1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 4, 25/Jan/2024
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 months old (n = 72) seemed to decrease compared to the same period in 2022 (n = 232). In 2023, hospitalised children’s mean age increased (14.4 months vs 7.8 months in 2022; p < 0.001) and hospital-stay length decreased (3.2 days vs 5.1 days; p < 0.001). In infants < 6 months old, intensive-care unit admissions appeared to drop (n = 28 vs 9). This suggests that nirsevimab prophylaxis reduced severe RSV infections, particularly in infants < 6 months old, thereby alleviating healthcare strain.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.4.2400033
2024-01-25
2024-12-21
/content/10.2807/1560-7917.ES.2024.29.4.2400033
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/4/eurosurv-29-4_2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.4.2400033&mimeType=html&fmt=ahah

References

  1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. , Respiratory Virus Global Epidemiology Network, RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64.  https://doi.org/10.1016/S0140-6736(22)00478-0  PMID: 35598608 
  2. Munkstrup C, Lomholt FK, Emborg HD, Møller KL, Krog JS, Trebbien R, et al. Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022. Euro Surveill. 2023;28(1):2200937.  https://doi.org/10.2807/1560-7917.ES.2023.28.1.2200937  PMID: 36695451 
  3. Broberg EK, Nohynek H. Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention. Euro Surveill. 2023;28(49):2300686.  https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300686  PMID: 38062943 
  4. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. , HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023;389(26):2425-35.  https://doi.org/10.1056/NEJMoa2309189  PMID: 38157500 
  5. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. , MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-46.  https://doi.org/10.1056/NEJMoa2110275  PMID: 35235726 
  6. European Medicines Agency (EMA). European Medicines Agency (EMA). Beyfortus (nirsevimab) An overview of Beyfortus and why it is authorised in the EU. Amsterdam: EMA; 2022. [Accessed 20 Dec 2023]. Available from: https://www.ema.europa.eu/en/documents/overview/beyfortus-epar-medicine-overview_en.pdf
  7. CDC Health Alert Network. Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023-2024 Respiratory Virus Season. Atlanta: CDC; 2023. [Accessed 8 Jan 2024]. Available from: https://emergency.cdc.gov/han/2023/han00499.asp
  8. Conseil supérieur des maladies infectieuses. Recommandations du Conseil supérieur des maladies infectieuses concernant l’immunisation passive contre le RSV par des nouveaux anticorps monoclonaux Juillet 2023. Luxembourg: Conseil supérieur des maladies infectieuses; 2023. [Accessed 20 Dec 2023]. Available from: https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/Infection-a-virus-respiratoire-syncitial-_RSV_/17072023-recommandation-csmi-rsv-immunisation-vf.pdf
  9. Règlement grand-ducal du 8 février 2023 modifiant le règlement grand-ducal modifié du 15 février 2019 portant énumération des maladies sujettes à déclaration obligatoire et fixant les délais de déclaration ainsi que les informations à reprendre au cahier des charges pour la désignation comme laboratoire national de référence d’un laboratoire d’analyses médicales. [Grand-Ducal Regulation of 8 February 2023 amending the amended Grand-Ducal Regulation of 15 February 2019 listing the diseases subject to mandatory notification and setting the reporting deadlines as well as the information to be included in the specifications for the designation of a medical analysis laboratory as a national reference laboratory]. French. Available from: https://legilux.public.lu/eli/etat/leg/rgd/2023/02/08/a85/jo
  10. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. , Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020;383(5):415-25.  https://doi.org/10.1056/NEJMoa1913556  PMID: 32726528 
  11. Koltai M, Krauer F, Hodgson D, van Leeuwen E, Treskova-Schwarzbach M, Jit M, et al. Determinants of RSV epidemiology following suppression through pandemic contact restrictions. Epidemics. 2022;40:100614.  https://doi.org/10.1016/j.epidem.2022.100614  PMID: 35901639 
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Corinna+Ernst&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ernst Corinna</a>, <a href="/search?value1=Dritan+Bejko&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bejko Dritan</a>, <a href="/search?value1=Leo+Gaasch&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gaasch Leo</a>, <a href="/search?value1=Emilie+Hannelas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hannelas Emilie</a>, <a href="/search?value1=Isaline+Kahn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kahn Isaline</a>, <a href="/search?value1=Charlotte+Pierron&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pierron Charlotte</a>, <a href="/search?value1=Nesrine+Del+Lero&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Del Lero Nesrine</a>, <a href="/search?value1=Claude+Schalbar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schalbar Claude</a>, <a href="/search?value1=Elsa+Do+Carmo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Do Carmo Elsa</a>, <a href="/search?value1=Michel+Kohnen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kohnen Michel</a>, <a href="/search?value1=Emmanuelle+Andlauer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Andlauer Emmanuelle</a>, <a href="/search?value1=Pauline+Hublart&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hublart Pauline</a>, <a href="/search?value1=Silvana+Masi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Masi Silvana</a>, <a href="/search?value1=Isabel++de+la+Fuente+Garcia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de la Fuente Garcia Isabel </a>, <a href="/search?value1=Anne+Vergison&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vergison Anne</a>, <a href="/search?value1=Jo%C3%ABl+Mossong&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mossong Joël</a></span>. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(4):pii=2400033. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 14 Jan 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 25 Jan 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.4.2400033
/content/10.2807/1560-7917.ES.2024.29.4.2400033
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error